Syngene International reported a 2% year-on-year rise in Q2FY26 revenue from operations to ₹911 crore and a 6% increase in H1 revenue to ₹1,785 crore. EBITDA stood at ₹215 crore with margins of 23.2%. Growth in research services offset lower biologics manufacturing volumes. The company secured its first global Phase III trial from a U.S.-based biotech and is expanding its Bengaluru biologics facility with a new GMP bioconjugation suite for Antibody Drug Conjugates. Syngene also earned top-tier global sustainability ratings, reaffirming its focus on responsible growth and scientific innovation

See Full Page